Slides
Page 1
ASX:ALA Non-deal roadshow July 2025 For personal use only
Page 2
ASX:ALA Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. 2. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. 3. Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. The presentation includes forward-looking statements regarding future events and the future financial performance of Arovella. Forward looking words such as “expect”, “should”, “could”, “may”, “predict”, “plan”, “will”, “believe”, “forecast”, “estimate”, “target” or other similar expressions are intended to identify forward-looking statements. Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, Arovella and its officers, employees, agents or associates. In particular, factors such as outcomes of clinical trials and regulatory decisions and processes may affect the future operating and financial performance of Arovella. This may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The information also assumes the success of Arovella’s business strategies. The success of the strategies is subject to uncertainties and contingencies beyond control, and no assurance can be given that the anticipated benefits from the strategies will be realised in the periods for which forecasts have been prepared or otherwise. Given these uncertainties, you are cautioned to not place undue reliance on any such forward looking statements. Arovella is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. 2 4. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. 5. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. 6. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change. 7. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which it would be unlawful. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed. For personal use only
Page 3
ASX:ALA Arovella’s strengths Off-the-Shelf iNKT Cell Platform Developing off-the-shelf iNKT cell therapies to target blood cancers and solid tumour cancers Strategic Acquisitions Focused on acquiring innovative technologies that strengthen its cell therapy platform and align with its focus areas Addressing Key Unmet Need Our iNKT cell platform is well positioned to solve key challenges that hamper the cell therapy sector Strong Leadership Group Leadership team and Board have proven experience in drug development, particularly cell therapies Clinic-ready Manufacturing Process Arovella has successfully developed a proprietary clinic- ready manufacturing process to produce CAR-iNKT cells ALA-101, potential treatment for CD19-positive blood cancers, progressing to phase 1 clinical trials, expected to commence in early 2026 Lead Product Advancing to Clinic 3 For personal use only
Page 4
ASX:ALA Arovella’s strong leadership group 4 Leadership Board of Directors Dr Michael Baker CEO & MANAGING DIRECTOR CHIEF OPERATING OFFICER Dr Nicole van der Weerden Dr Robson Dossa HEAD MANUFACTURING & QUALITY Dr Michelle Ferguson HEAD RESEARCH & DEVELOPMENT Jacqueline Cumming SNR DIRECTOR CLINICAL DEVELOPMENT Dr Elizabeth Stoner INTERIM CHAIR Dr Debora Barton DIRECTOR Mr Gary Phillips DIRECTOR For personal use only
Page 5
ASX:ALA Financial overview ASX CODE ALA Market capitalisation1 $136.7 million Shares on issue 1,188.6 million 52-week low / high $0.068 / $0.210 Cash Balance (30 Jun, 2025) $20.9 million Financial Snapshot 1. As of 24 July 2025 2. As of 21 March 2025 3. Holding includes associated entities and parties Major Shareholders Shareholder Ownership (%) 2 BIOTECH CAPITAL MANAGEMENT PTY LTD3 108,526,184 (9.17%) RICHARD JOHN MANN3 67,487,674 (5.70%) NETWEALTH INVESTMENTS LIMITED3 47,072,126 (3.98%) UBS NOMINEES PTY LTD 29,930,527 (2.53%) BLACKBURNE CAPITAL PTY LTD 23,008,988 (1.94%) 5 $0.00 $0.06 $0.12 $0.18 0 10,000,000 20,000,000 30,000,000 40,000,000 ALA Price and Volume - 12 Months1 For personal use only
Page 6
ASX:ALA Date Type of deal Acquirer/Licensee Target/Licensor Cell Type Stage Upfront (US$M) Milestones (US$M) Total deal value (US$M) Jun-25 Acquisition In vivo CAR Phase 1 $2,100 $0 Up to $2,100 Mar-25 Acquisition In vivo CAR Phase 1 $425 $575 $1,000 Nov-24 Acquisition Allo T cell Phase 1 ~$1,038 ~$462 $1,500 May-24 Research collaboration T cell TBD $50 $550 $600 Dec-23 Acquisition T Cell Phase 1b $1,000 $200 $1,200 Nov-23 Collaboration and investment2 Not specified Platform $25 $70-220 per product Aug-23 Licence3 T Cell Phase 1b $21 $206 $227 Aug-23 Strategic investment (ROFR) 4 T Cell Phase 1 $25 $0 $25 May-23 Licence T Cell Phase 1b $245 undisclosed Jan-23 Acquisition T Cell Phase 1 $200 $120 $320 Oct-22 Development collaboration5 T Cell Phase 2 $225 undisclosed Aug-22 Licence & strategic collaboration T Cell Phase 1 $110 $110 $220 Sep-21 Development collaboration T Cell Preclinical $150 $150 $300 Aug-21 Research collaboration iNKT Cell Preclinical undisclosed undisclosed $875 May-21 Acquisition iNKT Cell Phase 1 $70 $115 $185 Recent cell therapy transactions1 6 1. See the last slide for deal references; 2. Cellectis will receive a US$220m equity investment from Astra Zeneca plus tiered royalties. Milestones are payable for 10 products; 3. Precision is eligible for double digit royalties on net sales and $145 million in milestone payments and tiered royalties for additional programs; 4. Poseida also received a US$25m equity investment from Astellas; 5. Arcellx also received a US$100m equity investment from Gilead For personal use only
Page 7
ASX:ALA Highlights for CY 2025 to date… Cash and cash equivalents at 30 June, 2025 of $20.9 million 7 Completed $15 million placement to fully fund enrolment and report initial safety and efficacy data for the phase 1 trial for ALA-101 Successfully transferred the ALA-101 manufacturing process into cGMP environment in readiness for clinical batches Held the first meeting of the recently formed clinical advisory board Entered into sponsored research agreement with University of North Carolina to advance solid tumour and IL-12-TM armouring programs Generated functional Claudin 18.2-targeting chimeric antigen receptor Signed an exclusive Option for two new CARs targeting neuroblastoma and hepatocellular carcinoma For personal use only
Page 8
About CAR-T cells 8 For personal use only
Page 9
ASX:ALA Cell Therapy has revolutionised blood cancer treatment 9 CAR-T cells have demonstrated their curative potential in blood cancers Product Approval Year 2024 Revenue 2017 US$1570m3 2017 US$442m4 2021 US$242m5 1. https://www.businesswire.com/news/home/20230529005130/e n/Global-Cell-Therapy-Market-Report-2023-Advancements-in- Biotechnology-Drives-Growth---ResearchAndMarkets.com 2. Zinzi et al., 2023 Pharmacological Research - 10.1016/j.phrs.2023.106742 3. https://www.gilead.com/news/news-details/2025/gilead- sciences-announces-fourth-quarter-and-full-year-2024- financial-results. 4. https://www.novartis.com/sites/novartis_com/files/2025-01- interim-financial-report-en.pdf 5. https://ir.2seventybio.com/news-releases/news-release- details/2seventy-bio-reports-preliminary-full-year-us-abecma- sales-and The Cell Therapy market is expected to reach $61.2 billion by 20301 Strong Sales CAR-T cells have demonstrated ability to cure haematological cancers Cure Patients relapse post-CAR-T therapy2 40-60% For personal use only
Page 10
ASX:ALA Current CAR-T technology challenges One CAR-T product only treats the patient who supplied the T cells Manufacturing & supply chain costs are high T cells can be compromised due to disease Limited centres can collect and manufacture T cell T cell T cell T cell T cell 10 Patient must wait 3-4 weeks for therapy Time is an issue for patients with aggressive disease Manufacturing run failures can occur Each manufacturing batch is patient-specific ALA’s solution: One CAR-iNKT batch from a healthy donor treats multiple patients CAR-iNKT cell 1 week Patients ready to dose within 1 week For personal use only
Page 11
ASX:ALA Introducing invariant Natural Killer T (iNKT) cells 11 Bridging the innate and adaptive immune system Adaptive Immunity Innate Immunity For personal use only
Page 12
ASX:ALA iNKT cells represent a next-generation cell therapy 12 Properties make them ideal for use in cell therapy Strong safety profile Don’t cause graft versus host disease (GvHD) Front line of the human immune system Bridge innate & adaptive immune responses Contain both T cell & NK cell killing mechanisms Naturally target & kill cancers that express CD1d Multiple anti-cancer properties Shape the tumour microenvironment by blocking/killing pro tumour cells (TAMs/MDSCs) Infiltrate tumours & secrete signaling molecules to activate other immune cells to kill tumour cells Adaptive Immunity Innate Immunity For personal use only
Page 13
ASX:ALA A differentiated position 13 T cell and NK cell sectors are competitive Companies with T cell, NK cell, or iNKT cell therapy programs. Source: Company analysis based on public information NK cell T cell iNKT cell For personal use only
Page 14
ALA-101 (CAR19-iNKT cells) 14 A next generation off-the-shelf cell therapy for CD19 expressing cancers For personal use only
Page 15
ASX:ALA ALA-101: enhanced tumour killing in vivo 15 ALA-101 rapidly eradicates tumour cells in mice Tumour cells expressing CD19 and CD1d were intravenously delivered into mice Mice were treated with: PBS (saline) Unmodified T cells (T) Unmodified iNKT cells (iNKT) CAR19-T cells ALA-101 (CAR19-iNKT cells) After three days, ALA-101 resulted in significant regression of tumour cells In all other treatments, there was strong tumour cell persistence ALA-101 displays swift action iNKT ALA-101PBS T CAR19-T Day 0 3 Days after treatment Dorsal Ventral Dorsal Ventral Rotolo et al ., Cancer Cell (2018) For personal use only
Page 16
ASX:ALA ALA-101: next generation cell therapy 16 ALA-101 significantly increased survival in mice versus treatment with CAR19-T cells Tumour cells positive for CD19 and CD1d were intravenously delivered into mice Mice were treated with: PBS (saline) Unmodified T cells (T) Unmodified iNKT cells (iNKT) CAR19-T cells ALA-101 (CAR19-iNKT cells) After 90 days, only mice treated with CAR19-T cells or ALA-101 remained alive 1.5x more mice treated with ALA-101 remained alive after 90 days relative to CAR19-T cells ALA-101 has the potential to be an effective, off-the-shelf cell therapy for the treatment of CD19-positive cancers PBS (saline) (n=12) T cell (n=7) iNKT cell (n=7) CAR19-T cell (n=19) ALA-101 (n=19) P <0.01 Rotolo et al ., Cancer Cell (2018) For personal use only
Page 17
ASX:ALA ALA-101: spontaneous secondary remission 17 ALA-101 activity may persist to eradicate tumour cells following relapse Four mice treated with ALA-101 had the cancer return to the brain In all four mice, the cancer was eliminated a second time with no additional dosing This provides evidence that CAR19-iNKT cells can survive and continue to protect against cancer cells in vivo Potential to use ALA-101 to treat central nervous system lymphoma or brain metastases Dorsal Ventral Dorsal Ventral Rotolo et al ., Cancer Cell (2018) For personal use only
Page 18
ASX:ALA Clinic-ready manufacturing process developed 18 Semi-automated process suitable for large-scale and late-phase clinical development Completed GMP manufacture of ALA-101 lentivirus Lentivirus for any CAR Vial and freeze CAR-iNKT cells Expand to grow billions of CAR-iNKT cells Engineer iNKT cells to produce CARs Collect Healthy Donor Blood TECHNOLOGY ACQUISITION PRE-CLINICAL CONFIRMATION LENTIVIRUS MANUFACTURING FDA (IND) / TGA (CTA) PHASE 1 CLINICAL TRIAL PHASE 2 CLINICAL TRIAL MANUFACTURING PLATFORM Isolate iNKT cells Progressed tech transfer to the GMP suites for clinical manufacturingProgressed tech transfer to the GMP suites for clinical manufacturing High yield, >5,000-fold expansion of CAR-iNKT cells >99% purity of iNKT cells with a balance of CD4- and CD4+ cells Semi-automated, suitable for large-scale production Runs now being completed in the GMP suites using GMP reagents New knowledge becomes Arovella trade secret and IP New products can be created plug and play by substituting the lentivirus For personal use only
Page 19
ASX:ALA Taking ALA-101 into first-in-human trials 19 ALA is progressing towards its ALA-101-001 phase 1 study First Patient Dosed KOL engagement and Clinical trial design Engagement with key opinion leaders and potential sites and preparation of protocol synopsis IND-enabling studies and regulatory submission ALA is conducting IND-enabling non-clinical safety and efficacy studies to support regulatory approval Regulatory approval and site startup Once regulatory approval is obtained, sites will be activated and screening of patients can commence GMP manufacturing of clinical drug product ALA is finalising key GMP inputs and conducting process qualification in preparation for clinical manufacture Selection of clinical sites and CRO ALA will select participating sites and a clinical research organisation partner who will manage the study Abbreviations: CRO, Clinical research Organization; GMP, Good Manufacturing Practice; IND, Investigational New Drug Application; KOL, Key Opinion Leader Ongoing Ongoing Ongoing Clinical Advisory Board meeting held In vivo animal model completed Runs completed in GMP suites with GMP reagents For personal use only
Page 20
ASX:ALA ALA-101-001: phase 1 first-in-human study Patients with relapsed or refractory CD19+ non-Hodgkin’s lymphoma (NHL, including DLBCL, FL, MCL, MZL) and CD19+ leukemias (including B-ALL, CLL and HCL). Single dose of ALA-101 following lymphodepletion regimen Primary objectives To evaluate the safety and tolerability of ALA-101 in adult patients with CD19+ NHL or leukemia Secondary objectives To determine the most appropriate dose of ALA-101 for phase 2 clinical trials for adult patients with CD19+ NHL or leukemia To evaluate the preliminary efficacy of ALA-101 To characterise the pharmacokinetic (PK) profile of ALA-101 20 Dose escalation and dose expansion study in patients with CD19+ blood cancers Abbreviations: NHL, non-Hodgkin’s lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; B-ALL, B-cell acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; HCL, hairy cell leukemia Part 1: Dose Escalation Part 2 (phase 1b): Dose Expansion 4 dose levels ~9-12 patients total CD19+ lymphoma Dose level selected from Part 1 ~20 patients total Sub-indications selected from Part 1 For personal use only
Page 21
iNKT cells to target solid tumours Arovella is implementing its strategy to target and kill solid tumours – 90% of newly diagnosed cancer cases 1 1. https://www.cancer.gov/types/common-cancers 21 For personal use only
Page 22
ASX:ALA iNKT cells are naturally well placed to target solid tumours 22 1. Tachibana et al., 2005; 2. Molling et al., 2007; 3. Simonetta et al., 2021; 4. Zhou et al., 2024; 5. Heczey et al., 2023; 6. https://www.urologytimes.com/view/anti-cd70-car-nkt-therapy-shows-promise-in- renal-cell-carcinoma CAR = Chimeric Antigen Receptor; TME = Tumour Microenvironment iNKT cells have features that provide advantages in the complex solid tumour environment 1 iNKT cells naturally target CD1d, NKG2DL and other markers present on some tumour types. iNKT cell levels are prognostic for colorectal cancer and head and neck squamous cell carcinoma. 1,2 Naturally target cancer markers and are prognostic for survival 2 iNKT cells can influence the TME, induce cross-priming of other immune cells3, and CAR-iNKT cells have been shown to outperform CAR-T cells when tested using mouse models.4 Kill pro-tumour cells, activate helpful immune cells and outperform CAR-T cells 3 Infiltrate tumours and have shown promising clinical data in human solid tumour studies iNKT cells have been shown to infiltrate solid tumours and have shown promising data when tested in human clinical studies for a range of solid tumours, including neuroblastoma and renal cell carcinoma. 5,6 For personal use only
Page 23
ASX:ALA Arovella’s strategies to combat solid tumours 23 Arovella is using three approaches to expand the iNKT cell platform into solid tumours Identify and license new targets that are expressed in multiple cancers to incorporate into Arovella’s iNKT cell therapy platform License novel cancer targets Create unique partnerships Armour iNKT cells Enhance the performance of iNKT cells by equipping iNKT cells with novel armouring technologies Create partnerships to use novel combination therapies with synergistic effects For personal use only
Page 24
ASX:ALA Arovella has a clinic-ready manufacturing process to manufacture CAR-iNKT cells which can be leveraged to create many CAR-iNKT cell products to target multiple cancer types Add additional CARs for novel targets 24 Arovella’s manufacturing process can be leveraged for multiple cancer types New CARs MANUFACTURING for each new CAR e.g. CLDN18.2, GD2, GPC3 New lentivirus Vial and freeze CAR-iNKT cells Expand to grow billions of CAR-iNKT cells Engineer iNKT cells to produce CARs Isolate iNKT cells Collect Healthy Donor Blood New CAR genetic material – e.g. CLDN18.2, IL-12-TM and others For personal use only
Page 25
ASX:ALA Introducing Claudin 18.2 (CLDN18.2) 25 A promising solid tumour target with first monoclonal antibody approved in Japan and the US in 2024 Validated target market alone expected to reach $10.7 billion by 20311 Gastric cancer 1. https://www.alliedmarketresearch.com/gastric-cancer-market- A74458#:~:text=The%20global%20gastric%20cancer%20market,cells%20lining%20of%20the %20stomach CLDN18.2 overexpression has been identified in several types of cancers gastric cancer (GC) gastroesophageal junction cancer (GEJC) pancreatic cancer (PC) esophageal cancer (EC) ovarian adenocarcinoma (OAC) lung cancers (LC) Successfully generated a functional CAR that targets CLDN18.2 For personal use only
Page 26
ASX:ALA “Armouring” CAR-iNKT cells IL-12-TM (cytokine technology) enhances CAR-iNKT cell activity in solid tumours ARMOURING IL-12-TM IL-12-TM is a modified version of IL-12 with a membrane anchor that links it to the surface of CAR-iNKT cells. We have designed it to be attached to the surface of iNKT cells so that it can enhance CAR-iNKT cells without being released into the blood stream, making it safer. does not require changes to the manufacturing process The IL-12-TM is incorporated into the lentiviral vector and system and Arovella has entered into a Sponsored Research Agreement with Prof. Dotti’s group at the University of North Carolina iNKT cells IL-12-TM than CAR-iNKT cells lacking the cytokine Expand more and survive for longer 4 weeks after treatment in a mouse model 10x more circulating CAR-iNKT cells compared to CAR-iNKT cells lacking the cytokine Superior anti-tumour activity 26 Discover how our IL-12-TM cytokine technology works in our new IL-12-TM explainer whiteboard video. IL-12-TM For personal use only
Page 27
ASX:ALA Key benefits of IL-12-TM for CAR-iNKT cells 27 IL-12-TM enhances antitumor activity of CAR-iNKT cells Tumour cells positive for GD2 and were intravenously delivered into mice before treatment with CAR-iNKT cells Mice were treated with: PBS (saline) GD2-CAR GD2-CAR + IL-12 GD2-CAR + IL-12-TM After 60 days, only mice treated with GD2-CAR + IL12 or IL-12-TM remained alive IL-12-TM enhances CAR-iNKT cell numbers and antitumour activity *statistically significant (p=0.0344) Landoni et al ., Nature Communications (2024) PBS (n=4) GD2-CAR (n=4) GD2-CAR + IL-12 (n=4) GD2-CAR + IL12-TM (n=4) For personal use only
Page 28
ASX:ALA Arovella’s expanding pipeline 28 For personal use only
Page 29
ASX:ALA Commence phase 1 study and generate initial data from patients in early dose cohorts Upcoming milestones for FY2026 Jul 2025 Jun 2026 Complete cGMP manufacture and IND enabling studies and file an IND application with US FDA for phase 1 Complete preparatory activities for a first-in-human phase 1 study for ALA-101 in patients with CD19+ blood cancers Integrate IL-12-TM into solid tumour programs and test its efficacy in anti-tumour models Abbreviations: cGMP, current good manufacturing practice; FDA, Food and Drug Administration; IND, investigational new drug; CAR, chimeric antigen receptor; iNKT, invariant natural killer T Integrate the CLDN18.2 CAR into iNKT cells, and optimise the CAR for solid tumours Test CLDN18.2 targeting CAR-iNKT cells in gastric cancer and/or pancreatic cancer animal models ALA-101 (CD19) IL-12-TM integration ALA-105 (CLDN18.2) 29 Continue to identify and acquire novel technologies that enhance and expand Arovella’s iNKT cell therapy platform Option with Baylor College of Medicine to be exercised by Nov 2025 Pipeline expansion Arovella is funded to obtain preliminary safety and efficacy readouts for its phase 1 study of ALA-101 Dec 2025 Commence activities to manufacture ALA-105 for clinical trials (e.g. lentiviral vector production) For personal use only
Page 30
ASX:ALA Clinic-ready manufacturing process Arovella has successfully developed a proprietary clinic-ready manufacturing process to produce CAR-iNKT cells Summary 30 CAR-iNKT cells have anticancer properties CAR-iNKT cells have multiple anti-cancer properties that may support enhanced efficacy over other immune cell types, particularly against solid tumours Novel allogeneic CAR-iNKT cell platform iNKT cells serve as an excellent platform to develop allogeneic, or “off-the-shelf”, cell therapies to treat cancer Arovella has an expanding pipeline Arovella continues to expand the iNKT cell platform with the addition of a CLDN18.2 targeting CAR and its IL-12- TM armouring Arovella is poised for growth Arovella is developing a cutting-edge CAR-iNKT cell therapy platform, with an expanding pipeline and a strong leadership team Lead product progressing to clinical trials ALA-101, a potential treatment for CD19-expressing blood cancers, is being progressed to phase 1 clinical trials, expected to commence in early 2026 Arovella’s CAR-iNKT Cell Platform For personal use only
Page 31
ASX:ALA Thank You Dr. Michael Baker CEO & Managing Director Email: investor@arovella.com Mobile: +61 403 468 187 For personal use only
Page 32
ASX:ALA Cell therapy deal references 32 1. https://news.abbvie.com/2025-06-30-AbbVie-to-Acquire-Capstan-Therapeutics,-Further-Strengthening-Commitment-to-Transforming-Patient-Care-in- Immunologyhttps://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html 2. https://www.reuters.com/business/healthcare-pharmaceuticals/roche-acquire-us-based-poseida-therapeutics-2024-11-26/ 3. https://www.astellas.com/en/news/29166 4. https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and- autoimmune-diseases.html 5. https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-cell-and-gene-therapy-deal-w-cellectis.html 6. https://www.businesswire.com/news/home/20230815091930/en/Precision-BioSciences-Completes-Strategic-Transaction-with-Imugene-for-Azer-Cel-in-Cancer 7. https://www.astellas.com/en/news/28271 8. https://www.jnj.com/janssen-enters-worldwide-collaboration-and-license-agreement-with-cellular-biomedicine-group-to-develop-next-generation-car-t-therapies 9. https://www.astrazeneca.com/media-centre/press-releases/2023/acquisition-of-neogene-therapeutics-completed.html 10. https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/kite-and-arcellx-announce-strategic-collaboration-to-co-develop-and-co- commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myeloma 11. https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-strategic-global-collaboration-with-roche-focused-on-allogeneic-car-t-cell- therapies-for-hematologic-malignancies-301598555.html 12. https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/197/adaptimmune-enters-into-a-strategic-collaboration-with 13. https://www.gilead.com/news-and-press/press-room/press-releases/2021/8/kite-and-appia-bio-announce-collaboration-to-research-and-develop-allogeneic-cell- therapies-for-cancer 14. https://www.nasdaq.com/articles/athenex-snaps-up-kuur-therapeutics-for-$185m-street-sees-133.7-upside-2021-05-05 For personal use only